Doxorubicin HCl 10mg/vial, 20mg/vial, 50mg/vial; pwd for IV inj after reconstitution; contains lactose. Risk of cardiomyopathy (including left ventricular failure), arrhythmias. Pre-existing heart ...

The relentless efforts of Cuban doctor Miguel Ángel Ruano Sánchez to improve the health of young Damir Ortiz Ramírez have ...

In patients with advanced or recurrent endometrial cancer (EC) with previous exposure to carboplatin and paclitaxel (PT), ...

Race Oncology Ltd (ASX:RAC) has been approved for its Phase One trial of its chemotherapeutic candidate RC220 to treat people ...

The British biotechnology firm Avacta Therapeutics has reported significant progress with its lead drug candidate AVA6000, a modified form of the chemotherapy drug doxorubicin. In a recently ...

LadRx Corporation (OTCQB: LADX) (“LadRx” or the “Company”), a biopharmaceutical innovator focused on research and development of life-saving cancer therapeutics, is pleased to announce that Stephen ...

Avacta Therapeutics (AIM: AVCT), a life sciences company developing next generation peptide drug conjugates (PDC) targeting powerful anti-tumor payloads directly to ...

Race executes work order contract with contract research organisation George Clinical International to support a Phase 1 trial of its ... Read More The post Race inks key contract to advance trial of ...